Searched for
EBITDA METHODOLOGY
ET Prime Special Series: Multibagger or Bankrupt - Part 58: The ICE veteran that quietly became an EV lightweighting storyMost auto ancillary investors think linear. Company makes Component X. EV disrupts Component X. Stock goes down. Every story does not fit t...
ET Prime Special Series: Multibagger or Bankrupt - Part 56: An acquisition, a divestment, and a JV for EV. Ready for re-rating?Bulls argue this company is becoming a complete mobility-platform supplier in India: Power solutions and aftermarket, braking and safety. B...
Eternal, Swiggy shares rally 3% but HSBC just reduced target prices. Should you buy?Eternal and Swiggy shares rose after platform fee hikes, despite HSBC cutting target prices due to rising competition in quick commerce. Th...
LT Foods shares in focus as US slashes duty on soybean, eases liability by Rs 163 croreShares of LT Foods Ltd are in focus after the U.S. Department of Commerce sharply cut countervailing duty on its subsidiary’s organic soybe...
I-Sec upgrades Mahindra Logistics to Add; lowers target price to Rs 350ICICI Securities has upgraded Mahindra Logistics to 'ADD' with a revised target price of Rs 350, down from Rs 360. The upgrade is driven by...
Nomura upgrades Vodafone Idea, doubles target price. Should you buy?Vodafone Idea Target Price: Nomura has upgraded its rating on Vodafone Idea, expressing optimism that the worst is behind the company and i...
BofA takes a 'Buy' view on Paytm. Sees 20% upside in the new-age tech stockBank of America (BofA) Securities has given a 'Buy' rating for One 97 Communications, the parent company of Paytm, with a target price of R...
Nomura gives thumbs-up to MedPlus Health after Q2 showThe pharmacy major that runs full-service diagnostic centres in Hyderabad is planning a further capital allocation of Rs 9,000 lakh. "The c...
Pharma Industry staring at 30-40 bps hit on updated NLEMManchanda added that the anti-infectives treating HIV, TB and drug cessation treatments in the list doesn't have a major impact on margins ...
Buy GAIL (India) Ltd. target Rs 360: HDFC SecuritiesBuy GAIL (India) Ltd. at a price target of Rs 360.0 .
Buy GAIL (India) Ltd. target Rs 360: HDFC SecuritiesBuy GAIL (India) Ltd. at a price target of Rs 360.0 .
Stock pick of the week: Why analysts are bullish on Tata SteelReduced dumping from China, improving EBITDA growth in India and South East Asia, among other things, have made Tata Steel analysts’ top pi...
- Accumulate Larsen & Toubro, target Rs 2050: Yes Securities
Accumulate Larsen & Toubro Ltd. at a price target of Rs 2050. The priod given for reaching the target is one year
Raymond: Focus on branded offerings should help boost sales & profitability in long-termThough the management has no immediate plan for monetising Raymond’s 125-acre plot in Thane, but whenever it does so, it will be a trigger ...
- Our NMDC valuation throws up range of Rs 173-215/sh:HDFC
According to HDFC Securities fair valuation for NMDC lies is in the range of Rs 173-215 per share.
- Macquarie initiates coverage with an ‘Outperform’ on Jubilant
Macquarie initiates coverage with an ‘Outperform’ rating on Jubilant Organosys and a target price of Rs 450.
- Analysts'Picks: Tata chemicals
Goldman sachs initiates ‘buy’ recommendation on Tata Chemicals with a target price of Rs 435, implying 29% potential upside.